Background. Stepped care approaches are emphasized in guidelines for musculoskeletal pain, recommending less invasive or risky evidence-based intervention, such as manual therapy (MT), before more aggressive interventions such as opioid prescriptions. The order and timing of care can alter recovery trajectories. Objective. To compare oneyear downstream health care utilization in patients with spine or shoulder disorders who received only MT vs MT and opioids. The secondary aim was to compare differences based on order and timing of opioids and MT. Design. Retrospective observational cohort. Methods. Patients with an initial consultation for a spine or shoulder disorder who received at least one visit for MT were included. Person-level data from the Military Health System Management and Reporting Tool (M2) database were aggregated by a senior health care analyst at Madigan Army Medical Center. Groups were created based on the order and timing of interventions provided. Outcomes included health care utilization (medical costs and visits) over the year following initial consultation. Control measures included metabolic, mental health, chronic pain, sleep, and substance abuse comorbidities, as well as prior opioid prescriptions. Generalized linear models with gamma log links were run due to the heavily skewed nature of cost data. Results. From 1,876 unique patients with spine or shoulder disorders receiving MT, 1,162 (61.9%) also received prescription opioids. Mean one-year costs in the MT-only group ($5,410, 95% confidence interval [CI] ¼ $5,109 to $5,730) were significantly lower than in the MTþopioid group ($10,498, 95% CI ¼ $10,043 to $10,973). When patients had both treatments, mean one-year costs in the MT-first ($10,782, 95% CI ¼ $10,050 to $11,567) were significantly lower (P ¼ 0.030) than opioid-first ($11,938, 95% CI ¼ $11,272 to $12,643), and MT-first had a significantly lower mean days' supply of opioids (34.2 vs 70.9, P < 0.001) and mean number of unique opioid prescriptions (3.1 vs 6.5, P < 0.001). Conclusions. MT alone resulted in lower downstream costs than with opioid prescriptions. Both the order of treatment (MT before opioid prescriptions) and the timing of treatment (MT < 30 days) resulted in a significant reduction of resources (costs, visits, and opioid utilization) in the year after initial consultation. Clinicians should consider the implications of first-choice decisions and the timing of care for treatment choices utilized for patients with spine and shoulder disorders.
Background
Effectively managing pain from musculoskeletal disorders is a tremendous challenge for clinicians worldwide in both military and civilian settings. In the United States, musculoskeletal disorders account for 26% of outpatient provider visits in the military, with over half of these visits attributable to spine or shoulder conditions [1] . Reports from civilian health care systems in the United States find that spinal pain is the most common musculoskeletal condition for which medical care is sought [2, 3] and one of the top 10 causes for years lived with disability in every country out of 188 assessed in a recent global burden of disease study [4] . Shoulder disorders are also common [5] and often occur in conjunction with spinal disorders, especially those of the thoracic and cervical spine [6, 7] .
Costs associated with treatment of musculoskeletal conditions are high and continue to increase. Musculoskeletal disorders are reported to be the fifth most costly health condition in the United States, with an estimated $188 billion spent on management in 2013 [8] . In the US Military Health System (MHS), musculoskeletal conditions also impose substantial economic burden and detract from readiness [9] . Numerous pharmacologic and nonpharmacologic therapies are promoted in practice guidelines for musculoskeletal conditions in the MHS and civilian health care organizations [10] . A stepped care approach is generally advocated as a strategy to begin care, emphasizing less intensive, lower-risk, evidence-based options, with intensification limited to patients who are nonresponsive to firstline treatments [11, 12] . Manual therapy (MT), a low-risk firstline treatment option, is recommended by clinical practice guidelines for musculoskeletal conditions [10, 13, 14] and utilized frequently in the management of spine and shoulder disorders [7] . It refers to the "hands on" movement of joints and/or soft tissues by the clinician, with the intent of providing a therapeutic effect, and is utilized most by physicians, chiropractors, and physical therapists. Prescription opioids are also used frequently to manage pain associated with musculoskeletal disorders despite recommendations against initiating opioids as a firstline treatment [10, 15] .
Evidence is mounting that firstline treatment decisions can be highly consequential with respect to long-term outcomes and treatment costs for patients with musculoskeletal pain [16, 17] . For example, initiation of opioid therapy as a firstline treatment in contradiction to guideline recommendations is associated with prolonged recovery and higher health care costs [18] . A recent report found that when opioids were prescribed early for patients with low back pain, concurrent treatment from physical therapists, who also typically use MT, reduced risk for long-term opioid use over the next year [19] . That study did not investigate MT specifically, nor did it consider other outcomes beyond long-term opioid use or conditions other than low back pain. The specific role of MT and the interaction between concurrent opioid and MT use are topics requiring further investigation. Improved understanding of the downstream impact of firstline treatment decisions may highlight opportunities to improve care.
The primary aim of this study was to compare downstream health care utilization (health care visits, costs, and opioid use) in two groups of patients with musculoskeletal spine and shoulder pain: 1) patients who received MT only vs 2) patients who received MT plus opioid therapy. The hypothesis was that patients who received only MT would have lower downstream medical visits and costs than patients who received both MT and opioids. The secondary aims were to examine downstream health care utilization based on order of care in those who received both MT and opioids: 1) MT before opioids vs 2) opioids before MT; and based on timing of care: 1) MT or 2) opioid prescriptions occurring within or after 30 days of the initial medical consultation date (index date). The hypothesis was that for patients receiving both interventions, those receiving MT before receiving an opioid prescription would have lower downstream costs, medical visits, and opioid utilization compared with those who received opioid prescriptions before MT. In addition, those receiving MT earlier, within 30 days, were hypothesized to also have less downstream health care utilization (visits and costs) and less opioid utilization than those receiving MT after 30 days.
Methods
This was an observational cohort study design following patients at a single hospital in the Military Health System (MHS) who were seeking care for spine or shoulder pain with the index care visit occurring between January 1, 2009, and December 31, 2009.
Data Sourcing and Reporting
This study cohort was identified using health care utilization data from the MHS Management and Reporting Tool (M2) database. The M2 captures patient-level medical data for all beneficiaries in the closed, single-payer US Military Health System. This includes care provided within military treatment facilities and care occurring in civilian hospitals when TRICARE is the payer. All inpatient and outpatient visits and pharmaceutical prescription data are captured by M2, as well as costs for each medical visit or health care service. Costs of care represent amounts assigned by TRICARE for each procedure within the military hospitals and actual reimbursed cost of care for all procedures in civilian hospitals. The cost of providing care in military facilities comes from the US Department of Defense operating budget, and therefore costs are assigned to each element of care for accounting purposes [20] . The REporting of studies Conducted using Observational Routinely collected health Data (RECORD) [21] extension of the Strengthening The Reporting of OBservational studies in Epidemiology (STROBE) statement was used to guide the reporting of this study. The study was approved by the Institutional Review Board at Madigan Army Medical Center.
Identification of Study Sample and Dependent Variables
We identified patients between the ages of 18 and 65 years seeking initial care for a spine or shoulder diagnosis at Madigan Army Medical Center with the presence of a relevant code based on the International Classification of Diseases, 9th Edition. In clinical practice, patient presentation is not always clearly defined or isolated to a single body region or complaint. Shoulder pain often manifests because of or alongside cervical or thoracic spine disorders. In this cohort, <10% had isolated shoulder symptoms. Therefore, individuals seeking care for both shoulder and spine disorders were included to improve generalizability of actual individuals presenting in these clinics. To prioritize resources for active duty service members and their dependents, patients older than age 65 years are often send out to care in civilian networks, especially as most will have become Medicare eligible. The specific spine and shoulder ICD-9 diagnosis codes used for cohort identification have been published [7] . To identify a patient seeking initial care for shoulder or spine pain (i.e., an index visit), we excluded any patient with a health care visit associated with a spine or shoulder ICD-9 code in the 12 months prior and anyone not fully eligible for benefits in the year after the index visit. We excluded patients who did not have at least one visit that included an MT treatment in the 12-month period following the index visit. MT is a common treatment utilized in the MHS for these disorders [7] and is identified using Current Procedural Terminology codes 97140, 98925-98929, and 98940-98943, delivered by physical therapists, osteopathic physicians, or chiropractors. Details of the cohort identification have been published elsewhere [7] .
We created two initial comparison groups: 1) those who only received MT (MT-only) and 2) those who received MT and opioids (MTþopioids) during the 12-month period following the index date. Use of opioids was identified using the American Hospital Formulary Service (AHFS) codes 280808 and 280812. For assessing order of care, we examined individuals in the MTþopioids group and further categorized them into 1) those for whom the date of the first MT code preceded the date of the first opioid prescription order vs 2) those for whom the date of the first opioid prescription order preceded MT. Patients receiving opioid prescriptions and MT on the same day were not included in the analysis. Finally, to assess timing of care, we categorized patients as receiving MT or opioids within or after 30 days of their initial index, as this typically reflects the time frame for an initial course of care. These groupings created two primary comparison groups and six secondary comparison groups. Outcome variables included total outpatient health care visits and costs, spine-and shoulder-related health care visits and costs, and opioid utilization (number of prescription orders placed and total days' supply) over the course of one year after the index visit.
We did not exclude individuals based on the presence of comorbidities, but instead reported the incidence within each group and used them as covariates for adjustment in our statistical models. Specifically, we identified disorders of metabolism, mental health, sleep, substance abuse, and chronic pain present after initial spine or shoulder diagnosis, and opioid utilization in the year prior to initial diagnosis. This was a dichotomous variable, flagged as present if at least one diagnostic code in that category was recorded in a medical encounter. Identification of comorbidities was based on relevant ICD-9 codes, and the methodology has previously been published [20] .
Statistical Approach
Chi-square and Fisher exact tests were run for nominal and interval-level comparison between groups. Health care utilization costs and counts are typically heavily skewed, with the majority of individuals utilizing smaller amounts of health care and the minority utilizing a greater amount of health care [22] . Due to the nature of this non-normal distribution of data, we utilized generalized linear models (GLMs) to compare each set of two groups (three separate group comparisons), with gamma log links for cost data (total health care costs and spineor shoulder-related health care costs) and with negative binomial regression for count data (health care visits, spine-or shoulder-related health care visits, opioid prescriptions, and days' supply of opioids) [23] . Adjustments were made for baseline demographic variables and comorbidities that were different between groups by placing these variables as covariates in the GLMs. Point estimates with 95% confidence intervals were reported where appropriate, and significance was set at <0.05. Data were available for all individuals, so no one was lost to follow-up.
Results
During the period of surveillance, 7,566 unique patients sought care for a musculoskeletal shoulder or spine condition, and 1,876 (24.8%) received MT at least once as part of their treatment and were included in the final cohort (41.5% female, mean age ¼ 36.9 6 10.9 years). Health care utilization and cost data for relevant outcomes from the 12 months before and 12 months after index diagnosis were available in the M2 database for all individuals in this final cohort. From this cohort, 1,162 (61.9%) were also prescribed opioids (453 had MT first; 671 had opioid prescriptions first). From the 1,876 total subjects, 803 (42.8%) had their first MT visit within 30 days of initial consultation, and 1,073 (57.2%) had it after 30 days. From the 1,162 who had opioid prescriptions, 530 (45.6%) had opioids within the first 30 days of consultation, and 632 (54.4%) had them after 30 days. Baseline demographics between all groups are shown in Table 1 .
The primary aim of this study was to compare oneyear downstream health care utilization in patients with spine or shoulder disorders who received only MT vs MT and opioids. Comparisons between patients receiving MT with or without opioids are outlined in Table 1 . Variables that were different between subjects at baseline and adjusted as covariates in the models included age, sex, beneficiary status, opioid use in the year before the index visit, and presence of a comorbidity in the year before the index visit. Patients in the MTþopioids group were younger, more likely to be male and active duty, and had a higher comorbidity burden than patients who only received MT ( (Table 2) . Spine and shoulder outpatient health care visits (mean difference ¼ 6.69, 95% CI ¼ 5.38 to 8.00) and health care costs specific to care for spine and shoulder conditions (mean difference ¼ $1,494, 95% CI ¼ $1,281 to $1,708) were also higher in the MTþopioids group, as well as utilization of urgent care, spine radiographs, and advanced imaging ( Table 2) .
Our secondary aim was to compare differences based on order and timing of opioids and MT. Among 1,162 patients in the MTþopioids group, 38 received the treatments on the same day and were not considered in further analyses. From the remaining 1,124 patients, 671 (59.7%) were prescribed opioids first and 453 (40.3%) had MT first. Patients receiving opioids first were more likely to be male, active duty, and to have a higher comorbidity burden, particularly mental health, sleep disorders, and chronic pain conditions (Table 1) . Patients who received opioids first had a higher number of spine and shoulder outpatient health care visits (mean difference ¼ 4.40, 95% CI ¼ 2.40 to 6.40) and health care costs specific to care for spine and shoulder conditions (mean difference ¼ $931, 95% CI ¼ $606 to $1,295) than those receiving MT first (Table 2) . Patients receiving opioids first also had a greater average days' supply of opioids over the 12-month follow-up period (mean difference ¼ 36.62 days, 95% CI ¼ 29.39 to 43.85) and fewer opioid prescription fills (mean difference ¼ 3.37, 95% CI ¼ 2.64 to 4.10) ( Table 2 ). The median time to the first opioid prescription in patients who received opioids before MT was seven days, whereas the median time to first opioid prescription for those who received MT first was 158 days. Patients with only MT or MT before opioids had significantly fewer visits to the emergency room, advanced spine imaging scans (magnetic resonance imaging [MRI] or computed tomography [CT]), and radiographs ( Table 2) .
Assessment of the associations between outcomes and timing of each intervention are outlined in Tables 3 and  4 . Among patients receiving MT, 803 (42.8%) had MT within 30 days of the index visit. Patients receiving early MT had fewer health care visits and lower health care costs across all outcomes when compared with patients receiving MT beyond 30 days (Table 3) . Patients receiving early opioids had a higher number of health care visits for spine conditions and higher relative health care costs related to care for spinal conditions, as well as increased numbers of opioid fills and total days' supply of opioids over the one-year follow-up period (Table 4) .
Health care utilization rates progressively increased between groups from early MT as the group with the lowest use of resources, to any MT use in general, and then to opioid use as the group with the highest utilization of resources. (Figure 1 ).
Discussion
The cost-savings associated with a model that followed a stepped care approach were apparent in this cohort. Patients receiving opioid prescriptions as the first line of care, contrary to guideline recommendations, had greater downstream health care utilization in the year following the index visit. When first-step recommended care (MT) was provided before opioids were prescribed, or within 30 days of the index visit, downstream health care utilization was significantly less in the year following the index visit, supporting the guideline recommendation of MT as a first line of treatment. In this cohort, receiving MT alone as a treatment for spine or shoulder disorders was associated with decreased downstream medical costs compared with individuals who received both MT and opioid prescriptions. These results may reflect the increased severity of patients who progress beyond firstline care to require more aggressive, second-line treatments for pain, like prescription opioids.
The impact of the timing and sequencing of interventions for musculoskeletal pain is not fully understood. Studies involving patients with cervical [24] and lumbar spine disorders [25] [26] [27] have found that initial management decisions can impact a patient's long-term prognosis and predict the extent of downstream health care utilization and costs [28] , including whether a patient will become a chronic opioid user [19] . In this cohort, we found similar results. Patients who received MT within 30 days of initial consultation had significantly less downstream health care utilization and lower costs than those who also received MT after 30 days. Early opioid utilization compared with opioid utilization beyond 30 days, however, did not result in similar findings. Early opioid use was associated with significantly higher health care utilization (spine visits and costs) compared with delayed opioids (Table 4) . Patients utilizing opioids in this cohort, regardless of timing, had higher health care costs and utilization than any subgroup of patients who received MT. We then further examined the role of the sequencing of MT and opioid treatments. Our finding that receiving MT before opioids was associated with lower health care costs and utilization supports the stepped care model, which considers MT to be a firstline treatment, with opioids as a second-line therapy. Thus, our results suggest the importance of timing for the firstline treatment of MT, with early provision (within 30 days) associated with lower health care costs and utilization, and the importance of sequencing with respect to the second-line treatment of opioid prescribing, with provision after MT associated with fewer spine and shoulder health care visits and lower costs. Although MT is a recommended firstline treatment for patients with spine or shoulder conditions, early use of this treatment was uncommon in this cohort. The median number of days from the first medical visit to the first MT treatment in this cohort was 44 days, indicating that MT is not often considered a first line of treatment.
The order of interventions aligns well with the recommended stepped care model. However, when assessing not only order but timing of the intervention, there were also significant differences in downstream health care utilization for MT, but not for opioids. Patients who had an initial MT treatment within 30 days of the initial visit Values represent mean (95% confidence interval), unless otherwise noted, and were adjusted for age, sex, beneficiary category, dichotomous opioid use in the year before seeking care, and dichotomous presence of any comorbidity in the year after seeking care. *Significant difference between groups: P < 0.05.
had significantly less downstream utilization for all health care variables (costs and visits) (Table 3) . However, earlier opioid utilization (<30 days) did not result in any reductions in downstream health care utilization compared with patients taking opioids later (>30 days). In some cases, early opioid use actually resulted in significantly higher health care utilization (spine visits and costs) compared with delayed opioids (Table 4) . Downstream health care utilization in the opioid utilizers, regardless of early or delayed, was still higher than any group that included MT. Some research has suggested that early nonadherent care may be better than later adherent care when it comes to specific types of physical therapy interventions [26] , insinuating that managing patients in a timely manner may be more important than the specifics of the intervention. The results from this cohort indicate that both order of care and timing of care were able to significantly discriminate downstream health care utilization, but timing of care was only favorable for MT, a firstline recommended treatment.
Other care elements considered costly and potentially risky were higher in patients who did not receive guideline-concordant care. The relative risk (RR) of having an MRI or CT ordered for their spine was much higher for patients who also had opioids (RR ¼ 5.38, 95% CI ¼ 2.60 to 11.11) compared with those who only had MT without opioids (Table 2 ). Advanced imaging is often considered a metric of quality care for back pain, as the results can identify findings of questionable relevance [29] , are only actionable 13% of the time [30] , and are often a key driver of increased downstream costs and greater risk for more aggressive procedures [31] . In the absence of specific red flags, guidelines recommend their use only after an initial course of conservative management has failed [31] . The risk of having an emergency room visit was also higher for those with opioid and MT compared with MT alone.
Not surprisingly, a significantly higher number of individuals in the MTþopioids group (53.9%) used opioids in the year prior compared with the MT-only group (31.2%). Rates of all comorbid conditions were also higher at baseline in the MTþopioid group compared with the MT-only group. When examining the timing of care in patients who received both MT and opioids, those receiving opioids before MT had more mental health, chronic pain, substance abuse, and sleep disorders than those who had MT before opioids. These differences could account for some of the differences in downstream health care utilization; however, there were still significant differences between groups after adjusting for prior opioid use and presence of comorbidities.
The majority of baseline variables were significantly different between the two initial groups (MT-only vs MTþopioids), so potentially the patients in the group with opioids had a more chronic or complex problem and had been seen for a longer period of time. The duration of symptoms and chronicity of the problem cannot be identified with the nature of these data. However, the index visit in this cohort was defined as a visit without a prior visit for one of these conditions in the previous 12 months. Therefore, if this was a more chronic problem, the individuals were not seeking relevant medical care for the problem the entire year prior or may have been receiving care for a musculoskeletal disorder in a different body region.
Limitations
It is important to consider when interpreting these results that the data are observational and causality cannot be implied. The results rely heavily on the interpretation of the researchers, and there may have been other confounding variables that could not be accounted for in the statistical models. It is possible that utilization or timing of other interventions not assessed in this study may have had the same or better impact on downstream health care utilization or accounted more for the differences seen. The duration of symptoms and chronicity of the problem would improve interpretation of the results but cannot be identified with the nature of these data. The presence of comorbidities before the index date may have influenced the outcomes as well and was not accounted for; however, their presence after the index date was likely most relevant to the outcomes investigated. The quality of the data extracted from medical records is also limited to the quality by which it was entered by clinicians. Having said that, these are the same data that drive business case analyses and reports for the Military Health System and US Defense Health Agency. Finally, these data come from care patterns within the Military Health System, and the results may not be generalizable to other settings (e.g., this is a single-payer system; approximately half of the sample were military service members).
Conclusions
Following recommended firstline treatments for spine or shoulder pain resulted in significantly less downstream health care utilization and lower costs. MT alone was better than MT plus opioid utilization. Both the order of treatment (MT before opioid prescriptions) and the timing of treatment (MT < 30 days) resulted in a significant reduction of resources (costs, visits, and opioid utilization) in the year after initial consultation. Clinicians should consider the implications of first-choice decisions and the timing of care for treatment choices utilized for patients with spine and shoulder disorders.
